ArticleBlood advances2020
How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 115 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplantation (REMM-HIIT-HCT)
ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients (ACTivate)
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Micronutrient requirements for stem cell transplantation patients > 100 days after transplant and during graft versus host disease: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Donor-derived malignancy after allogeneic stem cell transplantation: a rare but well recognized complication.Bone marrow transplantation · 2025Pooled it
- Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.Bone marrow transplantation · 2022Pooled it
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.Transplantation and cellular therapy · 2021Pooled it
- A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.Bone marrow transplantation · 2026Trial
- Trial
- FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.Blood advances · 2024Trial
- The prognostic value of patient-reported outcomes in allogeneic hematopoietic stem cell transplantation: exploratory analysis of a randomized nutrition intervention trial.Annals of hematology · 2023Trial
- Trial
- Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in Japan: changes in practice patterns and outcomes during the past 20 years.International journal of hematology · 2026Article
- Article
- A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.Bone marrow transplantation · 2026Article
- Preemptive hematopoietic stem cell transplantation inHaematologica · 2026Article
- Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis.Bone marrow transplantation · 2026Article
- System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.Transplantation and cellular therapy · 2026Article
- Clinical translational research on stem cell products: prospects and challenges.Signal transduction and targeted therapy · 2026Review
- Association of Cyclosporine Dose with Early Onset Hypertension in Allogeneic Hematopoietic Cell Transplant Patients: A Cohort Study.Journal of clinical medicine · 2026Article
- Hemophagocytic Lymphohistiocytosis Triggered byClinical case reports · 2026Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a study to find out how advances in modern medicine have improved the mortality risk of allogeneic stem cell transplantation. We analyzed major transplantation outcome parameters in adult patients on the European Society for Blood and Marrow Transplantation (EBMT) registry who had hematologic malignancies and had received transplants from matched sibling donors. We performed multivariate analyses using the Cox proportional-hazards model including known risk factors for nonrelapse mortality and a matched-pairs analysis. We identified 38 800 patients who fulfilled the inclusion criteria. Considerable changes in patient characteristics have occurred in the past decades, such as older age, different underlying diseases, and a higher proportion of patients with advanced disease. Major reasons for transplantation-related death in the 1980s were infectious complications and graft-versus-host disease. Nonrelapse mortality, measured at 1 year after transplantation, has decreased over time: 29.7% from 1980 through 1989, 24.4% from 1990 through 1999, 14.8% from 2000 through 2009, and 12.2% from 2010 through 2016. On multivariate analysis, the year of transplantation was associated with reduced nonrelapse mortality (P < .0001; hazard ratio [HR] [95% confidence interval (CI)], 0.8 [0.79-0.82], for 5-year intervals) and decreased overall mortality (P < .0001; HR [95% CI], 0.87 [0.86-0.88]. In the matched-pairs analysis of 3718 patients in each group, nonrelapse mortality at 1 year was 24.4% in the 1990s and 9.5% from 2013 through 2016 (P < .0001; HR [95% CI], 0.39 [0.34-0.43]). Transplantation-related mortality has decreased significantly in the past 40 years. These favorable data facilitate evidence-based treatment decisions on transplantation indications in the context of the availability of novel immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.